{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T06:42:51Z","timestamp":1784875371503,"version":"3.55.0"},"reference-count":41,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,6,11]],"date-time":"2012-06-11T00:00:00Z","timestamp":1339372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2012,7]]},"abstract":"<jats:p><jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold><\/jats:p><jats:p>\u2022\u2003A recent meta\u2010analysis has suggested an increased risk of cancer among users of angiotensin receptor blockers.<\/jats:p><jats:p><jats:bold>WHAT THIS STUDY ADDS<\/jats:bold><\/jats:p><jats:p>\u2022\u2003Within the limitations of an observational study there is no difference in the cancer incidence between users of drugs affecting the renin\u2010angiotensin system and users of other antihypertensives.<\/jats:p><jats:p>\u2022\u2003No consistent dose or duration dependency could be demonstrated for angiotensin reeptor blockers and angiotensin converting enzyme inhibitors.<\/jats:p><jats:p><jats:bold>AIMS<\/jats:bold> A recent meta\u2010analysis of clinical trials has demonstrated a small excess of cancers in persons who had been allocated to angiotensin receptor blockers (ARBs). We undertook this observational study to look at dose\u2013response and dose\u2013duration effects and look for specificity with respect to outcome. Use of angiotensin converting enzyme inhibitors (ACEIs) was included in the main analysis since ACEIs share pharmacological properties with ARBs.<\/jats:p><jats:p><jats:bold>METHODS<\/jats:bold> We identified 149\u2003417 incident cancer cases in Denmark during the period 2000\u20132005. Four controls, matched by age and gender, were selected for each case by a risk\u2010set sampling. Data on medication were retrieved from the Danish National Prescription Registry. We defined long term exposure as at least 1000 defined daily doses redeemed within the past 5 years. Confounders were controlled by conditional logistic regression.<\/jats:p><jats:p><jats:bold>RESULTS<\/jats:bold> The odds ratio (OR) associating long term drug use with incident cancer was 1.12 (95% CI 1.06, 1.18), 1.17 (95% CI 1.14, 1.20), 1.23 (95% CI 1.20, 1.26), 1.18 (95% CI 1.14, 1.22), 1.25 (95% CI 1.22, 1.28), 1.37 (95% CI 1.21, 1.54), 1.29 (95% CI 1.22, 1.37) for ARBs, ACEIs, calcium channel blockers, \u03b2\u2010adrenoceptor blockers, thiazide diuretics and \u03b1\u2010adrenoceptor blockers. No consistent dose\u2013duration or dose\u2013response association could be demonstrated for ARBs or ACEIs.<\/jats:p><jats:p><jats:bold>CONCLUSIONS<\/jats:bold> The indication or possibly threshold for prescribing antihypertensives appears to be related to a small increase in cancer risk. The ARB\u2010cancer association is probably too weak to be addressed in observational studies, given their limitations.<\/jats:p>","DOI":"10.1111\/j.1365-2125.2012.04170.x","type":"journal-article","created":{"date-parts":[[2012,1,13]],"date-time":"2012-01-13T16:56:58Z","timestamp":1326473818000},"page":"180-188","source":"Crossref","is-referenced-by-count":59,"title":["Long term use of drugs affecting the renin\u2010angiotensin system and the risk of cancer: a population\u2010based case\u2010control study"],"prefix":"10.1111","volume":"74","author":[{"given":"Jesper","family":"Hallas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren","family":"Friis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Bjerrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,6,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00750.x"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2005.07.009"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026043387818"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.2174\/1570161043385556"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0129com"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14282-1"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70106-6"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)03228-0"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)80084-0"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05704-X"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011101)92:9<2462::AID-CNCR1596>3.0.CO;2-L"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11663"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.910"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.3.349"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1023\/B:CACO.0000036152.58271.5e"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jhh.1001000"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-005-9091-x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10294"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.3317\/jraas.2000.002"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1053\/euhj.2001.2729"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602490"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.007336"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-08-0646"},{"key":"e_1_2_6_25_2","first-page":"535","article-title":"The Danish Cancer Registry \u2013 history, content, quality and use","volume":"44","author":"Storm HH","year":"1997","journal-title":"Dan Med Bull"},{"key":"e_1_2_6_26_2","first-page":"263","article-title":"The Danish National Hospital Register. A valuable source of data for modern health sciences","volume":"46","author":"Andersen TF","year":"1999","journal-title":"Dan Med Bull"},{"key":"e_1_2_6_27_2","first-page":"445","article-title":"The Danish prescription registries","volume":"44","author":"Gaist D","year":"1997","journal-title":"Dan Med Bull"},{"key":"e_1_2_6_28_2","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health 2011.ATC\/DDD index. Available athttp:\/\/www.whocc.no\/atc_ddd_index\/(last accessed 12 February 2012)."},{"key":"e_1_2_6_29_2","first-page":"78","volume-title":"Epidemiology, an Introduction","author":"Rothman K","year":"2002"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"e_1_2_6_31_2","volume-title":"Stata for Windows","author":"Stata Press","year":"1999"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199108013250501"},{"key":"e_1_2_6_33_2","first-page":"266","article-title":"Accuracy of ovarian cancer ICD\u201010 diagnosis in a Danish population\u2010based hospital discharge registry","volume":"26","author":"Tetsche MS","year":"2005","journal-title":"Eur J Gynaecol Oncol"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00008469-200506000-00002"},{"key":"e_1_2_6_35_2","unstructured":"Danish Medicines Agency 2011.Statistics prices and reimbursement. Available athttp:\/\/medstat.dk\/(last accessed 12 February 2012)."},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh160"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.328.7440.634"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7618077"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.epirev.a036146"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70260-6"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1052"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14596-5"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2012.04170.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2012.04170.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T23:10:35Z","timestamp":1697411435000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2012.04170.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,11]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["10.1111\/j.1365-2125.2012.04170.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04170.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6,11]]}}}